Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
一项针对2b期和3期HPTN 083随机对照试验的二次分析，比较了长效卡博特韦与每日口服富马酸替诺福韦酯加恩曲他滨预防男男性行为者（包括顺性别男性和跨性别女性）HIV感染的疗效和安全性，该分析基于研究揭盲后1年的数据。
期刊:Lancet HIV
影响因子:13
doi:10.1016/S2352-3018(23)00261-8
Landovitz, Raphael J; Hanscom, Brett S; Clement, Meredith E; Tran, Ha V; Kallas, Esper G; Magnus, Manya; Sued, Omar; Sanchez, Jorge; Scott, Hyman; Eron, Joe J; Del Rio, Carlos; Fields, Sheldon D; Marzinke, Mark A; Eshleman, Susan H; Donnell, Deborah; Spinelli, Matthew A; Kofron, Ryan M; Berman, Richard; Piwowar-Manning, Estelle M; Richardson, Paul A; Sullivan, Philip A; Lucas, Jonathan P; Anderson, Peter L; Hendrix, Craig W; Adeyeye, Adeola; Rooney, James F; Rinehart, Alex R; Cohen, Myron S; McCauley, Marybeth; Grinsztejn, Beatriz
